| This week's sponsor is Premier Research. | | | Taking the Fight to Rare Cancers
Beating rare cancers demands expertise in oncology and rare diseases. Our white paper shows how adaptive design, study committees, and cross-industry cooperation are fueling real progress. Premier Research. Built for biotech. |
Today's Rundown Celgene pays Immatics $75M to work on solid tumor cell therapies HiFiBiO raises $67M in Kite-backed series C round Autolus drags on Arix after weak period for CAR-T player Zealand Pharma signs on new CFO, expands into new digs Eye-tracking tests can help diagnose, gauge severity of concussions: study CRISPR slows the growth of triple-negative breast cancer in mice Featured Story | | | Wednesday, August 28, 2019 Celgene has paid Immatics $75 million upfront to collaborate on the development of anti-cancer adoptive cell therapies. The deal gives Celgene the chance to opt in to T-cell treatments for solid tumor programs once they reach candidate selection. |
|
|---|
|
Top Stories Wednesday, August 28, 2019 HiFiBiO Therapeutics has raised a $67 million series C round to advance its pipeline of oncology and autoimmune candidates. IDG Capital led the round with the support of a clutch of other existing and new investors, including Gilead’s CAR-T unit Kite. Wednesday, August 28, 2019 The problems facing CAR-T startup Autolus Therapeutics have infected one of its key investors, Arix Bioscience. Arix reported a 15% drop in its net asset value (NAV) as a result of the fast-falling share price of the troubled British biotech. Wednesday, August 28, 2019 As Zealand Pharma ramps up its clinical work and looks toward the market, the Danish company has hired Matthew Dallas as its chief financial officer and pulled the trigger on a relocation after spending 20 years at its current site. Wednesday, August 28, 2019 A new study shows that RightEye's eye-tracking technology, FDA-cleared for “recording viewing and analyzing eye movements in support of identifying visual tracking impairment in patients," could provide doctors a way to diagnose concussion. Monday, August 26, 2019 A team of researchers at Boston Children's Hospital has developed an innovative way to knock out the oncogene Lipocalin 2 using the editing system CRISPR and has shown its potential for treating triple-negative breast tumors in mice. | This week's sponsor is ExL Events. | | | |
Enrollment Showcase | | | October 23-25, 2019 | Chicago, IL | Presented by Biotech Primer BioImmersion: Biotech for the Non-Scientist is a three-day, in-depth course that delves into the scientific details on a broad number of biotechnology topics. Register today! |
|
|---|
|
Resources Sponsored by: Alexander Group From sales headcount and budgets to new product launches and saying “yes” to millennials, hear the top 7 topics that are trending in sales compensation. Sponsored by: Wesco Pharmaceutical Solutions and WBR Insights The regulations and managing processes for hazardous, controlled and rare chemicals and biologics necessary for drug discovery are a huge distraction for R&D labs. Learn from the perspectives of industry executives the pain points and improvements they want in their processes for chemicals and biologics in pharmaceuticals R&D. Sponsored by: Kinaxis Download this life sciences industry spotlight to discover how concurrent planning can help you overcome complex supply chain challenges to drive down costs and improve efficiency. Sponsored by: Patheon, by Thermo Fisher Scientific Patheon, part of Thermo Fisher Scientific, offers advanced API manufacturing technologies such as continuous processing and continuous analytics to deliver high-quality products with well-defined features to meet your timelines and volume requirements. Sponsored by: ICON Understanding the challenges for formulary decision makers and manufacturers. Sponsored by: Veeva This white paper details how leveraging new reporting capabilities, live UAT feedback sessions, and an agile design approach to study builds will save them time and money. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Latin America Healthcare Compliance Certificate Program September 23-26, 2019 BioBasics: Biotech For The Non-Scientist Oct 22-23, 2019 | San Diego, CA BioImmersion: Biotech for the Non-Scientist October 23-25, 2019 | Chicago, IL 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register NOW and start Pre-Boot Camp Preparation! | 